Captrust Financial Advisors Tcr2 Therapeutics Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$2.11 - $2.94 $886 - $1,234	-420 Reduced 67.74%	200 $1,000
Q1 2022 May 16, 2022	BUY	$2.4 - $4.71 $892 - $1,752	372 Added 150.0%	620 $2,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $595 - $1,084	130 Added 110.17%	248 $1,000
Q3 2021 Nov 16, 2021	BUY	$8.44 - $18.35 $151 - $330	18 Added 18.0%	118 $1,000
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $2,038 - $3,407	100 New	100 $2,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.